{"id":29992,"date":"2023-01-14T09:09:30","date_gmt":"2023-01-14T09:09:30","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=category-publication&#038;p=29992"},"modified":"2024-02-26T16:21:23","modified_gmt":"2024-02-26T16:21:23","slug":"udgivelse-1","status":"publish","type":"publication","link":"https:\/\/amelie-project.eu\/da\/udgivelse\/udgivelse-1\/","title":{"rendered":"Celleformskarakteristika for humane skeletmuskelceller som en pr\u00e6diktor for myogen kompetence: Et nyt paradigme mod pr\u00e6cisionscelleterapi"},"content":{"rendered":"[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.21.0&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; width=&#8221;100%&#8221; sticky_enabled=&#8221;0&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.21.0&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<p><!-- divi:paragraph --><strong>Charlotte Desprez, Davide Danovi, Charles H Knowles og Richard M Day.<\/strong><\/p>\n<p>J. Tissue Eng. 2023;14:1-18.<\/p>\n<p><em>Abstrakt<\/em><\/p>\n<p><!-- divi:paragraph -->Skeletmuskelafledte celler (SMDC) har et enormt potentiale til at genopbygge dysfunktionelle muskler, der er g\u00e5et tabt p\u00e5 grund af sygdom eller traumer. Den nuv\u00e6rende terapeutiske brug af SMDC bygger p\u00e5 h\u00f8st af autologe celler fra muskelbiopsier, som efterf\u00f8lgende ekspanderes in vitro, inden de genindopereres i patienten. Heterogenitet kan skyldes flere faktorer, herunder kvaliteten af startbiopsien, alder og komorbiditet, der p\u00e5virker de behandlede SMDC'er. Kvalitetsattributter beregnet til klinisk brug fokuserer ofte p\u00e5 minimumsniveauer af myogen cellemark\u00f8rekspression. S\u00e5danne tilgange evaluerer ikke sandsynligheden for, at SMDC differentierer og danner myofibre, n\u00e5r de implanteres in vivo, hvilket i sidste ende afg\u00f8r sandsynligheden for muskelregenerering. Forudsigelse af den terapeutiske styrke af SMDC in vitro f\u00f8r implantation er n\u00f8glen til at udvikle vellykkede behandlinger inden for regenerativ medicin og reducere implementeringsomkostningerne. Her rapporterer vi om udviklingen af et nyt SMDC-profileringsv\u00e6rkt\u00f8j til at unders\u00f8ge populationer af celler in vitro, der stammer fra forskellige donorer. Vi udviklede en billedbaseret pipeline til at kvantificere morfologiske tr\u00e6k og udtr\u00e6kke celleformdeskriptorer. Vi unders\u00f8gte, om disse kunne forudsige heterogenitet i dannelsen af myotuber og korrelere med det myogene fusionsindeks. Flere af de tidlige celleformskarakteristika viste sig at korrelere negativt med fusionsindekset. Disse omfattede det samlede areal optaget af celler, arealform, afgr\u00e6nsende boksareal, kompakthed, \u00e6kvivalent diameter, minimum ferret-diameter, l\u00e6ngde af mindre akse og omkreds af SMDC 24 timer efter p\u00e5begyndelse af kulturen. De oplysninger, der er udledt med vores tilgang, viser, at levende cellebilleder kan registrere en r\u00e6kke cellef\u00e6notyper baseret p\u00e5 celleform alene, og at bevarelse af celleintegritet kan bruges til at forudsige tilb\u00f8jeligheden til at danne myotuber in vitro og funktionelt v\u00e6v in vivo.<\/p>\n<p><!-- \/divi:paragraph --><\/p>\n<p>F\u00e5 adgang til hele artiklen her:<\/p>\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36949843\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36949843\/<\/a><\/p>\n<p><!-- \/divi:paragraph --><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]","protected":false},"excerpt":{"rendered":"<p>Charlotte Desprez, Davide Danovi, Charles H Knowles and Richard M Day. J. Tissue Eng. 2023;14:1\u201318. Abstract Skeletal muscle-derived cells (SMDC) hold tremendous potential for replenishing dysfunctional muscle lost due to disease or trauma. Current therapeutic usage of SMDC relies on harvesting autologous cells from muscle biopsies that are subsequently expanded in vitro before re-implantation into the patient. Heterogeneity can arise from multiple factors including quality of the starting biopsy, age and comorbidity affecting the processed SMDC. Quality attributes intended for clinical use often focus on minimum levels of myogenic cell marker expression. Such approaches do not evaluate the likelihood of SMDC to differentiate and form myofibres when implanted in vivo, which ultimately determines the likelihood of muscle regeneration. Predicting the therapeutic potency of SMDC in vitro prior to implantation is key to developing successful therapeutics in regenerative medicine and reducing implementation costs. Here, we report on the development of a novel SMDC profiling tool to examine populations of cells in vitro derived from different donors. We developed an image-based pipeline to quantify morphological features and extracted cell shape descriptors. We investigated whether these could predict heterogeneity in the formation of myotubes and correlate with the myogenic fusion index. Several of [&hellip;]<\/p>","protected":false},"featured_media":31457,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:paragraph -->\n<p>Charlotte Desprez, Davide Danovi, Charles H Knowles and Richard M Day.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>J. Tissue Eng. 2023;14:1\u201318.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><em>Abstract<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Skeletal muscle-derived cells (SMDC) hold tremendous potential for replenishing dysfunctional muscle lost due to disease or trauma. Current therapeutic usage of SMDC relies on harvesting autologous cells from muscle biopsies that are subsequently expanded in vitro before re-implantation into the patient. Heterogeneity can arise from multiple factors including quality of the starting biopsy, age and comorbidity affecting the processed SMDC. Quality attributes intended for clinical use often focus on minimum levels of myogenic cell marker expression. Such approaches do not evaluate the likelihood of SMDC to differentiate and form myofibres when implanted in vivo, which ultimately determines the likelihood of muscle regeneration. Predicting the therapeutic potency of SMDC in vitro prior to implantation is key to developing successful therapeutics in regenerative medicine and reducing implementation costs. Here, we report on the development of a novel SMDC profiling tool to examine populations of cells in vitro derived from different donors. We developed an image-based pipeline to quantify morphological features and extracted cell shape descriptors. We investigated whether these could predict heterogeneity in the formation of myotubes and correlate with the myogenic fusion index. Several of the early cell shape characteristics were found to negatively correlate with the fusion index. These included total area occupied by cells, area shape, bounding box area, compactness, equivalent diameter, minimum ferret diameter, minor axis length and perimeter of SMDC at 24 h after initiating culture. The information extracted with our approach indicates live cell imaging can detect a range of cell phenotypes based on cell-shape alone and preserving cell integrity could be used to predict propensity to form myotubes in vitro and functional tissue in vivo.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Access the full paper here:&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36949843\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36949843\/<\/a><\/p>\n<!-- \/wp:paragraph -->","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[43],"class_list":["post-29992","publication","type-publication","status-publish","has-post-thumbnail","hentry","category-publication"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/publication\/29992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/types\/publication"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/media\/31457"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/media?parent=29992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/da\/wp-json\/wp\/v2\/categories?post=29992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}